Developer docs
API playgroundTry for free, no card

Search company profiles

Elixirgen Therapeutics

Full company profile

uuid00025vz

Namestring
Elixirgen Therapeutics
Legal namestring
Elixirgen Therapeutics, Inc.
Websiteurl
elixirgentx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company founded in May 2017 and headquartered in Baltimore, Maryland, that develops gene- and cell-based therapies for rare genetic diseases and aging-associated conditions. The company operates as a subsidiary of Elixirgen, LLC and is co-led by CEO Aki Ko and CSO/co-founder Minoru Ko, MD, PhD, the latter being the original discoverer of the ZSCAN4 mechanism at the National Institute on Aging (NIH). Its pipeline rests on two proprietary technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in an autologous cell therapy for Telomere Biology Disorders (lead candidate EXG-34217, in Phase I/II under NCT04211714), and Bobcat® mRNA, a single-strand mRNA design capable of carrying payloads over 13 kilobases — exceeding the ~4.7 kilobase ceiling of conventional AAV vectors and enabling delivery of full-length dystrophin for Duchenne muscular dystrophy (lead candidate EXG-7001, preclinical). EXG-34217 has been granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations, and early clinical data published in NEJM Evidence demonstrated the first-ever sustained telomere elongation in two treated patients.

Short descriptiontext

Elixirgen Therapeutics is a clinical-stage biotechnology company developing gene and mRNA therapies for rare genetic diseases and aging-associated conditions, with lead programs in Telomere Biology Disorders and Duchenne Muscular Dystrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy therapeutics, rare disease biotechnology, mRNA therapeutics platform, telomere biology disorders, duchenne muscular dystrophy therapy
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Therapy and mRNA Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company developing gene therapies. Revenue will be generated through commercialization of proprietary therapeutics for rare diseases and aging-associated conditions upon successful clinical development and regulatory approval.

sec.gov
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Elixirgen Therapeutics develops proprietary gene and mRNA-based therapeutic candidates for rare genetic diseases and aging-associated conditions. Its portfolio is anchored on two technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in its lead candidate EXG-34217 for Telomere Biology Disorders (Phase I/II), and Bobcat® mRNA, a single-strand mRNA delivery platform capable of carrying payloads over 13 kb used in EXG-7001 for Duchenne Muscular Dystrophy (preclinical). Revenue will be generated through out-licensing and strategic commercialization partnerships rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First-ever successful sustained telomere elongation in two EXG-34217-treated patients with Telomere Biology Disorder with no treatment-related safety concerns over 24-month and 5-month periods
+1 more record
Product overview1 text field

Elixirgen Therapeutics is a biotechnology company developing life-changing therapies for rare diseases and aging-associated diseases. Their product portfolio centers on two core technology platforms: ZSCAN4, a telomerase-independent telomere extension technology (lead candidate EXG-34217 in Phase I/II for Telomere Biology Disorders), and Bobcat® mRNA, a proprietary mRNA delivery platform capable of carrying large payloads over 13 kb (candidate EXG-7001 in preclinical stage for Duchenne muscular dystrophy).

Product and service2 records
1EXG-34217
CategoryGene therapy / cell therapy product candidate
Description

Autologous cell therapy product candidate using ZSCAN4 telomere extension technology for the treatment of patients with Telomere Biology Disorders; granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations; currently in Phase I/II clinical trial with early data published in NEJM Evidence demonstrating first-ever sustained telomere elongation in treated patients.

2EXG-7001
CategorymRNA therapeutic product candidate
Description

Bobcat® mRNA-based therapeutic candidate for Duchenne Muscular Dystrophy that encodes full-length dystrophin on a single mRNA strand; currently in preclinical phase with preclinical data demonstrating restoration of muscular function in DMD model mice and no safety findings associated with administration.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Nippon Shinyaku
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Elixirgen Therapeutics and Nippon Shinyaku entered into an option agreement for the development and commercialization of EXG-7001 for Duchenne Muscular Dystrophy. This strategic partnership enables Nippon Shinyaku to advance the Bobcat mRNA technology candidate in certain territories.

elixirgentx.com
2National Institute on Aging (NIH)
Strategic tierCoreTypeTechnology or Integration
Description

ZSCAN4 technology was originally discovered at the National Institute on Aging, a division of the National Institutes of Health, by Chief Scientific Officer Minoru Ko and his team. This discovery forms the foundation of Elixirgen's lead therapeutic program.

elixirgentx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase I/II clinical trial (NCT04211714) for ZSCAN4 (EXG-34217) is being conducted at Cincinnati Children's Hospital Medical Center to study the autologous cell therapy in Telomere Biology Disorders patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage developer of genetic medicines for Duchenne muscular dystrophy (Elevidys). Directly comparable as a DMD-focused therapeutics company pursuing gene-based approaches to large-gene monogenic disease.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV- and lentiviral-based therapies for rare monogenic diseases (e.g., Danon disease, Fanconi anemia, LAD-I). Closely comparable as a rare-disease gene therapy developer with a similar regulatory-designation strategy.

TypeDirect peer
Description

Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) pursuing genetic medicines for rare diseases. Comparable as a rare-disease genetic medicines developer with FDA-designated assets and a similar platform-to-product pipeline model.

4bluebird bio
TypeDirect peer
Description

Gene therapy developer focused on severe genetic diseases (sickle cell disease, beta-thalassemia, cerebral adrenoleukodystrophy). Directly comparable as a rare-disease gene and cell therapy developer navigating similar regulatory and commercialization pathways.

TypeDirect peer
Description

Clinical-stage gene therapy company leveraging its proprietary AAV delivery platform across rare and ophthalmic diseases. Comparable as a platform-based gene therapy developer, although Bobcat mRNA differentiates Elixirgen by using a non-viral large-payload approach.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cardiosphere-derived cells for Duchenne muscular dystrophy and other rare diseases. Directly comparable as a cell-therapy developer targeting DMD with rare-disease regulatory designations.

TypeEmerging player
Description

Clinical-stage developer of non-viral genetic medicines using lipid nanoparticles and cell-targeted DNA delivery for rare diseases. Comparable as a non-viral gene-delivery platform company addressing payload-size limitations of AAV — analogous to Elixirgen's Bobcat approach.

TypeDirect peer
Description

Clinical-stage genetic medicines company focused exclusively on Duchenne muscular dystrophy, including AAV-mediated gene therapy and other modalities. Directly comparable as a DMD-focused therapeutic developer competing in the same indication.

TypeDirect peer
Description

Clinical-stage genetic medicines company developing gene therapies, gene editing, and cellular reprogramming approaches for rare cardiac and neurological diseases. Comparable as a platform-based rare-disease genetic medicines developer.

TypeEmerging player
Description

Clinical-stage developer of in vivo gene editing therapies for cardiovascular disease using base-editing and lipid nanoparticle delivery. Comparable as a developer of next-generation genetic medicines using novel delivery/editing mechanisms rather than conventional AAV.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elixirgen Therapeutics

Gene Therapy and mRNA Therapeuticselixirgentx.com

Elixirgen Therapeutics is a clinical-stage biotechnology company developing gene and mRNA therapies for rare genetic diseases and aging-associated conditions, with lead programs in Telomere Biology Disorders and Duchenne Muscular Dystrophy.

What Elixirgen Therapeutics does

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company founded in May 2017 and headquartered in Baltimore, Maryland, that develops gene- and cell-based therapies for rare genetic diseases and aging-associated conditions. The company operates as a subsidiary of Elixirgen, LLC and is co-led by CEO Aki Ko and CSO/co-founder Minoru Ko, MD, PhD, the latter being the original discoverer of the ZSCAN4 mechanism at the National Institute on Aging (NIH). Its pipeline rests on two proprietary technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in an autologous cell therapy for Telomere Biology Disorders (lead candidate EXG-34217, in Phase I/II under NCT04211714), and Bobcat® mRNA, a single-strand mRNA design capable of carrying payloads over 13 kilobases — exceeding the ~4.7 kilobase ceiling of conventional AAV vectors and enabling delivery of full-length dystrophin for Duchenne muscular dystrophy (lead candidate EXG-7001, preclinical). EXG-34217 has been granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations, and early clinical data published in NEJM Evidence demonstrated the first-ever sustained telomere elongation in two treated patients.

Elixirgen Therapeutics firmographics

Firmographics
Name
Elixirgen Therapeutics
Legal name
Elixirgen Therapeutics, Inc.
Website
https://elixirgentx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Elixirgen Therapeutics is a clinical-stage biotechnology company developing gene and mRNA therapies for rare genetic diseases and aging-associated conditions, with lead programs in Telomere Biology Disorders and Duchenne Muscular Dystrophy.
Ownership category
akta.pro rank

Elixirgen Therapeutics industry classification

Industry
Product category
Gene Therapy and mRNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Gene therapy therapeutics
  • Rare disease biotechnology
  • MRNA therapeutics platform
  • Telomere biology disorders
  • Duchenne muscular dystrophy therapy

Where Elixirgen Therapeutics is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Elixirgen Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Therapeutic Development and Commercialization: Pre-revenue clinical stage biotechnology company developing gene therapies. Revenue will be generated through commercialization of proprietary therapeutics for rare diseases and aging-associated conditions upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Elixirgen Therapeutics product offering

Product offering

Core offering

Elixirgen Therapeutics develops proprietary gene and mRNA-based therapeutic candidates for rare genetic diseases and aging-associated conditions. Its portfolio is anchored on two technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in its lead candidate EXG-34217 for Telomere Biology Disorders (Phase I/II), and Bobcat® mRNA, a single-strand mRNA delivery platform capable of carrying payloads over 13 kb used in EXG-7001 for Duchenne Muscular Dystrophy (preclinical). Revenue will be generated through out-licensing and strategic commercialization partnerships rather than direct sales.

Product overview

Elixirgen Therapeutics is a biotechnology company developing life-changing therapies for rare diseases and aging-associated diseases. Their product portfolio centers on two core technology platforms: ZSCAN4, a telomerase-independent telomere extension technology (lead candidate EXG-34217 in Phase I/II for Telomere Biology Disorders), and Bobcat® mRNA, a proprietary mRNA delivery platform capable of carrying large payloads over 13 kb (candidate EXG-7001 in preclinical stage for Duchenne muscular dystrophy).

Differentiator

Problem solved

Functional benefit

Products and services

  • EXG-34217 Autologous cell therapy product candidate using ZSCAN4 telomere extension technology for the treatment of patients with Telomere Biology Disorders; granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations; currently in Phase I/II clinical trial with early data published in NEJM Evidence demonstrating first-ever sustained telomere elongation in treated patients.
  • EXG-7001 Bobcat® mRNA-based therapeutic candidate for Duchenne Muscular Dystrophy that encodes full-length dystrophin on a single mRNA strand; currently in preclinical phase with preclinical data demonstrating restoration of muscular function in DMD model mice and no safety findings associated with administration.

Quantifiable outcome

  • First-ever successful sustained telomere elongation in two EXG-34217-treated patients with Telomere Biology Disorder with no treatment-related safety concerns over 24-month and 5-month periods
  • +1 more outcomes

Companies that use Elixirgen Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Elixirgen Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Elixirgen Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Nippon ShinyakucoreStrategic or Co-development Partner · 1 January 2025Elixirgen Therapeutics and Nippon Shinyaku entered into an option agreement for the development and commercialization of EXG-7001 for Duchenne Muscular Dystrophy. This strategic partnership enables Nippon Shinyaku to advance the Bobcat mRNA technology candidate in certain territories.
  • National Institute on Aging (NIH)coreTechnology or IntegrationZSCAN4 technology was originally discovered at the National Institute on Aging, a division of the National Institutes of Health, by Chief Scientific Officer Minoru Ko and his team. This discovery forms the foundation of Elixirgen's lead therapeutic program.
  • Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development PartnerPhase I/II clinical trial (NCT04211714) for ZSCAN4 (EXG-34217) is being conducted at Cincinnati Children's Hospital Medical Center to study the autologous cell therapy in Telomere Biology Disorders patients.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Elixirgen Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Commercial-stage developer of genetic medicines for Duchenne muscular dystrophy (Elevidys). Directly comparable as a DMD-focused therapeutics company pursuing gene-based approaches to large-gene monogenic disease.
  • Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV- and lentiviral-based therapies for rare monogenic diseases (e.g., Danon disease, Fanconi anemia, LAD-I). Closely comparable as a rare-disease gene therapy developer with a similar regulatory-designation strategy.
  • Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) pursuing genetic medicines for rare diseases. Comparable as a rare-disease genetic medicines developer with FDA-designated assets and a similar platform-to-product pipeline model.
  • bluebird bio: Gene therapy developer focused on severe genetic diseases (sickle cell disease, beta-thalassemia, cerebral adrenoleukodystrophy). Directly comparable as a rare-disease gene and cell therapy developer navigating similar regulatory and commercialization pathways.
  • Regenxbio: Clinical-stage gene therapy company leveraging its proprietary AAV delivery platform across rare and ophthalmic diseases. Comparable as a platform-based gene therapy developer, although Bobcat mRNA differentiates Elixirgen by using a non-viral large-payload approach.
  • Capricor Therapeutics: Clinical-stage cell therapy company developing allogeneic cardiosphere-derived cells for Duchenne muscular dystrophy and other rare diseases. Directly comparable as a cell-therapy developer targeting DMD with rare-disease regulatory designations.
  • Solid Biosciences: Clinical-stage genetic medicines company focused exclusively on Duchenne muscular dystrophy, including AAV-mediated gene therapy and other modalities. Directly comparable as a DMD-focused therapeutic developer competing in the same indication.
  • Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies, gene editing, and cellular reprogramming approaches for rare cardiac and neurological diseases. Comparable as a platform-based rare-disease genetic medicines developer.

Emerging players

  • Generation Bio: Clinical-stage developer of non-viral genetic medicines using lipid nanoparticles and cell-targeted DNA delivery for rare diseases. Comparable as a non-viral gene-delivery platform company addressing payload-size limitations of AAV — analogous to Elixirgen's Bobcat approach.
  • Verve Therapeutics: Clinical-stage developer of in vivo gene editing therapies for cardiovascular disease using base-editing and lipid nanoparticle delivery. Comparable as a developer of next-generation genetic medicines using novel delivery/editing mechanisms rather than conventional AAV.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Elixirgen Therapeutics social profiles

Digital presence

Elixirgen Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elixirgen Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Elixirgen Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elixirgen Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elixirgen Therapeutics

What does Elixirgen Therapeutics do?

Elixirgen Therapeutics develops proprietary gene and mRNA-based therapeutic candidates for rare genetic diseases and aging-associated conditions. Its portfolio is anchored on two technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in its lead candidate EXG-34217 for Telomere Biology Disorders (Phase I/II), and Bobcat® mRNA, a single-strand mRNA delivery platform capable of carrying payloads over 13 kb used in EXG-7001 for Duchenne Muscular Dystrophy (preclinical). Revenue will be generated through out-licensing and strategic commercialization partnerships rather than direct sales.

Is Elixirgen Therapeutics a public or private company?

Elixirgen Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elixirgen Therapeutics founded?

Elixirgen Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Elixirgen Therapeutics based?

Elixirgen Therapeutics is headquartered in Baltimore, United States, in the North America region.

How does Elixirgen Therapeutics make money?

One revenue line is on record: therapeutic Development and Commercialization.

Who are Elixirgen Therapeutics's main competitors?

Direct peers on record are Sarepta Therapeutics, Rocket Pharmaceuticals, Krystal Biotech, bluebird bio, Regenxbio, Capricor Therapeutics, Solid Biosciences and Tenaya Therapeutics. Emerging players are Generation Bio and Verve Therapeutics.

Does Elixirgen Therapeutics have an API?

No public API is recorded for Elixirgen Therapeutics.

What industry is Elixirgen Therapeutics in?

Elixirgen Therapeutics's product category is Gene Therapy and mRNA Therapeutics. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyElixirgen builds rare disease pipeline around telomeres and DMDElixirgen Therapeutics entered an option agreement with Nippon Shinyaku on June 26 for EXG-7001, a preclinical full-length dystrophin mRNA therapeutic for Duchenne muscular dystrophy, with Nippon Shinyaku funding development and potentially obtaining exclusive worldwide commercialization rights. Separately, Elixirgen published Phase 1/2 data on February 25, 2025 showing sustained telomere elongation and increased absolute neutrophil counts in two patients with telomere biology disorders treated with EXG-34217, with no treatment-related adverse events reported over follow-ups of 24 months and five months. The FDA has granted EXG-34217 Orphan Drug, Regenerative Medicine Advanced Therapy, and Rare Pediatric Disease designations.GenengnewsElixirgen Builds Rare Disease Pipeline Around Telomere Biology Disorders and DMDElixirgen Therapeutics, at BIO 2026, highlighted its telomere biology disorder and DMD pipeline. It announced an option agreement with Nippon Shinyaku for EXG-7001, a locally administered full-length dystrophin mRNA, and its lead TBD candidate EXG-34217 is in Phase I/II testing. The company has raised about $34 million.PR NewswireNippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular DystrophyNippon Shinyaku Co., Ltd. has entered into an option agreement with Elixirgen Therapeutics, Inc. to obtain exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapeutic for Duchenne muscular dystrophy. EXG-7001 is a locally administered drug that expresses full-length human dystrophin protein and is currently in preclinical development. Elixirgen is preparing for clinical trials in the United States, and following exercise of the option and regulatory approval, NS Pharma intends to commercialize the treatment.GlobeNewswireElixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular DystrophyElixirgen Therapeutics has entered into an option agreement with Nippon Shinyaku for the development and commercialization of EXG-7001, an mRNA therapeutic for Duchenne Muscular Dystrophy. Under the terms, Elixirgen will lead development while Nippon Shinyaku funds costs and may obtain exclusive worldwide commercialization rights, with Elixirgen receiving an upfront payment plus potential development and sales-based milestones. NS Pharma, a wholly owned subsidiary of Nippon Shinyaku based in the United States, will handle marketing and commercialization following regulatory approval.GlobeNewswireElixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular DystrophyElixirgen Therapeutics entered an option agreement with Nippon Shinyaku to develop EXG-7001 for Duchenne Muscular Dystrophy, with Nippon Shinyaku funding development and receiving exclusive worldwide commercialization rights. Elixirgen will get an upfront payment and milestone payments if the option is exercised.SecSEC FORM DElixirgen Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The company raised a total of $6,999,988 through the issuance of Series A-3 Preferred Units and convertible securities, with one non-accredited investor participating in the transaction.BioSpaceElixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of DirectorsElixirgen Therapeutics appointed Jeffrey L. Cleland, Ph.D., to its Board of Directors. He brings 30 years of industry experience and currently leads Ashvattha Therapeutics. The company plans to advance its EXG-34217 program in telomere biology disorders.SecSEC FORM DElixirgen Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates a total offering amount of $5,000,000 USD, with the first sale occurring on September 14, 2022. The company is based in Baltimore, Maryland, and is classified within the biotechnology industry.PR NewswireElixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated DiseasesElixirgen Therapeutics, a Baltimore-based biotechnology company, has entered into an exclusive three-year research collaboration with Taisho Pharmaceutical to advance potential treatments for aging-associated diseases using Elixirgen's proprietary ZSCAN4 therapy platform. The partnership combines Elixirgen's novel therapy platform with Taisho's experience in therapeutic product research and development. Elixirgen is currently conducting a Phase I/II clinical trial for telomere biology disorders with bone marrow failure, a rare orphan disease, at Cincinnati Children's Hospital Medical Center.